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Summary
The expression of the 70-kD 0 subunit of the interleukin 2 receptor (IL2R) has been examined
on peripheral blood lymphocytes (PBL) obtained from patients receiving systemic infusions of
11,2. Using monoclonal antibodies directed against p70, flow cytometric analyses revealed a greater
than threefold increase in expression of the IIr2R 0 chain on CD56+ natural killer (NK) cells
from post-IL2 therapy PBL relative to pre-therapy cells . The level of p70 expression on the post-
therapy cells was three- to fourfold greater (based on fluorescence intensity) than the level of
p70 expression on YT cells, an NK-like cell line that expresses -12,000 intermediate affinity
IL2 binding sites/cell . Despite the high level of p70 expression, in 1251-IL2 binding assays only
790-1,290 intermediate affinity IL2 binding sites/cell were detected on post-therapy cells from
six patients . These data represent the first report of increased p70 expression after in vivo 11,2
administration and suggest a requirement for at least one additional subunit for the formation
of functional intermediate affinity IL2Rs. Furthermore, thepresence on the surface ofpost-therapy
NK cells ofexcess p70 that does not bind 11,2 with intermediate affinity implies that the formation
of intermediate affinity I1r2Rs is not solely determined by the level of p70 expression, and that
the response of NK cells to IL2 might be regulated by altering the expression of p70 or some
other I1r2R subunit .
L2, originally characterized as the active component in T
cell growth factor, has been found to have stimulatory effects
on cells of multiple hematopoietic lineages . As such, IL2Rs
have been identified on T cells, B cells, NK cells, peripheral
blood monocytes, macrophages, and early granulocytes (1) .
11r2Rs are composed of at least two chains, a 55-kD ci chain
(Tac) (2-8) and a 70-75-kD0chain (p70) (9-14) . The chains
independently bind IL2 with either low (Tac ; Kd = 5-15
nM) or intermediate (p70 ; Kd = 0.5-2 nM) affinity, while
the noncovalent association o£ the two chains results in the
generation of an IL2R complex with high affinity binding
properties (Kd = 5-10 pM) (9-16) . Cellular responses to
IL2, including ligand internalization, are mediated by both
high and intermediate affinity receptors and appear to require
a chain participation (1, 6, 11, 15-23) .
Unstimulated T cells express only very low numbers of
high affinity IL2Rs. Activation of these cells with antigenic
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or nonspecific mitogenic stimuli, however, results in increased
IL-2 and Tac synthesis, followed by a rapid increase in high
affinity IL2R expression (1, 24) . This activation also leads
to increased release of soluble Tac protein from the cells (25) .
Similar results were noted when purified T cells were cul-
tured directly in IL2 (1, 19, 24, 26) . The latter observation
suggests that IL2, when present in sufficient concentrations,
directly activates resting Tac- cells through the intermediate
affinity p70 0 chain, leading to the synthesis of IL2 and Tac
and the formation of Tac/p70 IL-2R complexes . Subsequent
autocrine responses to IL-2 would then be mediated by the
newly formed high affinity receptors. Consistent with these
in vitro observations, increased levels of soluble Tac have been
observed in the sera of patients receiving systemic infusions
ofhigh-dose 11,2 (27, 28), in the sera of patients experiencing
graft rejections (29), and in other forms of in vivo immune
activation (30) .
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gesting that IL-2 activation of these cells may occur exclu-
sively through the p70 a chain of the IIr2R (22, 31-33) .
Recent studies have further demonstrated that the majority
of the resting NK cells are CD16'CD56dim and bind IL-2
through p70 . However, a small subset of restingNK cells
is distinguishable phenotypically as CD566"ghtCD16 - , and
these cells bear high affinity IL2Rs (34, 35) . Whether ex-
pansion of one or both of these subsets resulted in the in-
creased Tac expression observed after exposure ofresting NK
cell populations to IL-2 in vitro (11, 20-22) is not known .
The functional role of these distinct NK cell subsets is
also unclear, although it has been suggested that the
CD16 -CD56 6°ghc subset bearing the high affinity IL2R
may represent a precursor population capable of expanding
and differentiating in response to low physiologic concentra-
tions of 11,2 that occur naturally in vivo (34, 35) . This hy-
pothesis is also attractive with regard to the in vivo immune
activation observed in patients who have achieved steady-state
serum IL2 levels of -30 U/ml during continuous infusions
of 11,2 for the treatment of cancer (36) .
The exposure of heterogeneous populations of lympho-
cytes to high concentrations of IIr2 activates a non-MHC-
restricted cytolytic activity due to the expansion of a pop-
ulation of large granular lymphocytes with properties of
activated NK cells (36-38) . The cells mediating this lym-
phokine activated killer activity effectively lyse fresh tumor
targets as well as various NK-resistant cultured tumor cell
lines (38) . This observation, together with the demonstra-
tion of in vivo efficacy in murine tumor models, has led to
testing ofIL2 as a therapeutic modality (36, 37, 39) . In clin-
ical trials at anumber of institutions, patients with renal cell
carcinoma and melanoma have shown objective regression
of tumor in response to a variety of IL-2 treatment regimens
(39-43) .
In an effort to better characterize and modify further the
in vivo effects of systemically administered IL-2, we have ex-
amined changes in lymphocyte function and phenotype after
IL-2 therapy. Enhanced proliferative and cytotoxic activity in
response to 11,2 treatment in vitro was observed with PBL
obtained after IL-2 therapy (44-46) . These responses were
mediated primarily by the CD56' NK cell subpopulation,
a subset of the circulating lymphocytes that is significantly
expanded in number during the course ofin vivo 11,2 therapy
(45-48) . The increased levels of soluble Tac detected in pa-
tients' sera during IL2 therapy (27), together with increases
in the percentage of Tac' PBL after therapy (45-47), sug-
gested that the majority of the CD56' cells might be re-
sponding through receptors containing the Tac protein. Ex-
posure to 11,2 in vitro leads to Tac induction on resting
peripheral blood NK cells obtained from control donors, or
from patients before beginning 11,2 therapy. However, the
CD56' NK cell population activated by IL-2 in vivo, when
cultured in I1,2 in vitro, proliferated without subsequent cell
surface expression of Tac (44) . The proliferative response to
IL2 of lymphocytes obtained after IL-2 therapy was inhibited
by the anti-p70 mAbTU27 (49), while an antiTacmAb had
a negligible effect, suggesting a predominant role for the p70
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(3 chain in the responses of post-IL-2 therapy PBL to IL2
(44) . We now report the direct examination ofIL-2R a chain
expression before and after 11,2 therapy and present the first
evidence for increased expression of the II1,2R (3 chain in re-
sponse toin vivo 11,2 . We further demonstrate that the high
level of expression of p70 is not accompanied by a corre-
sponding high level of intermediate affinity IL-2 binding sites,
suggesting a requirement for some additional molecule in
the formation of functional intermediate affinity IL2Rs.
Materials and Methods
Patients.
￿
All patients enrolled in this phase I clinical trial had
locally recurrent renal cell carcinoma or malignant melanoma that
was incurable by surgery. Patients received 11,2 at 1-3 x 106
U/m2/d as a 96-h continuous infusion for four consecutive weeks.
Clinical and immune response data from this treatment regimen
have been reported elsewhere (50) . All patients signed consent forms
for in vivo and in vitro studies approved by the University ofWis-
consin Committee for the Protection ofHuman Subjects . Patient
PBMC (PBL) were obtained by Ficoll-Hypaque separation of
heparinized blood specimens drawn before initiating, or 24 h after
each 4-d cycle of IL2, cryopreserved by controlled rate freezing
in10% DMSO, and stored at -135'C until later use . Unless stated
otherwise, pretherapyPBL refers to PBL obtainedjust before starting
any IL2 treatment, and post-therapy PBL are cells obtained 24 h
after finishing 4 wk of IL2 .
11,2.
￿
rI1r2 was generously provided by Hoffmann-La Roche,
Inc . (Nutley, NJ) . All IL-2 units are based on the National Cancer
Institute-Biological Response Modifiers Program standard for unit
determination . The specific activity of HLR 11,2 is 1.5 x 107
U/mg protein .
Antibodies.
￿
FITC- and PE-conjugated mAbs (anti-CD25[Tac]-
FITC, anti-CD16[Leu-11a]-FITC, anti-CD5-FITC, anti-CD56[Leu-
19]-PE, anti-CD3-PE) and FITC-conjugated goat anti-mouse IgG
(GAM-FITC)t were purchased from Becton Dickinson Monoclonal
Center (Mountain View, CA) . GL439 is a mouse IgG1mAb directed
against the p55 Tac chain ofthe humanIL2R (51) . TU27 is a mouse
IgG1 mAb directed against the p70 /3 chain of the human IL2R
(49) . Mik (31 (IgG2a) and Mik (33 (IgGl) are also directed against
the p70 IL2R0 chain (52). Ascites fluid containing IgGI and IgG2a
isotype control mAbs (MOPC21 and UPC10, respectively) were
purchased from Sigma Chemical Co. (St . Louis, MO) .
Cell Lines.
￿
YT is an NK-like cell line established from a pa-
tient with acute lymphoblastic lymphoma and thymoma (53), and
was generously provided by J . Yodoi, Kyoto University. YT cells
are negative for expression of the T cell antigen CD3 and express
NK cell markers detected by the anti-CD16 (FcR) and anti-CD56
mAbs . YT expresses a relatively high number (-12,000/cell) of
intermediate affinity IIr2R (3 chains (12, 13) .
Flow Cytometric Analysis.
￿
For single-color fluorescence analysis
with either TU27, Mik /31, or Mik /33, 106 cells were incubated
in 100 p.l of a 1:4,000 dilution of ascites fluid containing TU27
or a 1:1,000 dilution of ascites fluid containing either Mik ,31 or
Mik (33 . The dilution buffer was HBSS, 1% FCS, 0.2% NaN3 .
Serial dilutions of the ascites fluids have been made up to 1:4,000
(TU27) and 1:1,000 (Mik 01 and Mik /33) with no change in staining
pattern . After 30-60 min on ice, antibody was removed, cells were
washed, and resuspended in 100,ul ofdilution buffer. GAM-FITC
' Abbreviations used in this paper : GAM, goat anti-mouse ; MFI, median log
fluorescence intensity.wasaddedat 1hg/mlfor30 min, cellswere washed andresuspended,
and analyzed immediately. For two-color fluorescence, cells were
first stained as describedabove with appropriate dilutions ofascites
fluid containing either TU27, Mik (31, or Mik 03. After GAM-
FITC staining, thecellswere incubatedfor 10 minon icein HBSS,
1% FCS, and 0.2% NaN3 containing 10,ug/ml purified control
mouse IgG1 (MOPC 21; Sigma Chemical Co.) to block any free
antibody binding siteson thebound GAM-FITC molecules. After
blocking, cellswere stained with either anti-CD3-PE or anti-CD56-
PE for 30 min on ice, washed, and analyzed by flow cytometry.
Control staining of TU27/GAM-FITC-stained cells with a PE-
conjugated isotype control antibody showed no nonspecific staining
dueto recognition ofthePE-conjugated antibodies by boundGAM-
FITC molecules (unpublished observations). All samples were ana-
lyzedon aFACScanflow cytometer (Becton Dickinson& Co.) using
FACScanResearch and Consort 30 Software. All samples were gated
on forwardandside scatter. Propidium iodide was added at 1tag/ml
before analysis to allow exclusion of dead cells.
Median log fluorescence intensity (MFI)calculations were per-
formed by subtracting theMFIofappropriate isotype control anti-
bodies from the MFI of the positively stained samples. Thus, all
MFI values presentedrepresentrelative increases in log fluorescence
intensity over a background value assigned 0, allowing compar-
isons to be made between individual populations.
FACS.
￿
Freshlyobtained, Ficoll-Hypaque-separated PBL were
resuspended in HBSS containing 100U/ml penicillinAtreptomycin,
and 0.3% BSA. 1.8 x 108 cells were resuspended at 2.0 x 10'/ml
and stainedwith anti-CD56-PE andanti-CD5-FITC. Afterrotating
for 60 min at 4°C, the cells were washed twice and resuspended
at a final concentration of 5 x 106/ml. Before cell sorting cells
were passed through a Nytex membrane to achieve a single cell
suspension. Sorting was performed on a FACStarPl°' flow cytom-
eter (Becton Dickinson & Co.). Purity of the CD56*- and CD5*-
sorted populations was >99% upon restaining and reanalysis.
For purification of larger numbers of CD56* cells (>5.0 x
10'), negative depletions were performed using the anti-CD3 mAb
OKT3 (Ortho Pharmaceuticals, Raritan, NJ) and immunomag-
neticbeads coupledto GAM IgG(Dynal Beads; Dynal, Inc., Great
Neck, NY). Bead depletions were performed as described previ-
ously (44). Reanalysis of CD3-depleted cells with anti-CD5 and
anti-CD56 revealed purity of >95%.
Fc Receptor Blocking.
￿
Rabbit Ig (Sigma Chemical Co.) was
resuspended at 20 mg/ml in HBSS andheat aggregated for30 min
at 65°C as described (54). Patient PBL (5 x 106) were incubated
in 200F.1 HBSS containing 10 mg/ml aggregated rabbit Ig for 2 h
at 4°C. Lower concentrations of rabbit IgG were not effective at
blocking staining by anti-FcR mAbs (anti-CD16[Leu-11] directed
against FcyRIII present on NK cells; S. Voss, unpublished obser-
vations). Aliquots ofcells were then removed and stained with ei-
ther TU27, anti-CD16, anti-CD3, anti-CD56, or isotype control
mAbs. FACS analyses were performedas described above. Neither
monomeric rabbit or human Ig, nor aggregated human Ig, were
found to be as effective as aggregated rabbit Ig in interacting with
theFcRs expressedon NK cells (S. Voss, unpublished observations).
Incubation of the patient's cells with rabbit Ig also had no effect
on staining with anti-CD3 or anti-CD56.
FACS Analysis With Biotinylated H,2-lys.
￿
IIr2-lys-biotin was
generously provided byDr. Paul Simon, GlenoldenLaboratory E.I.
DuPont de Nemours&Co. (Glenolden, PA) andhasbeen described
previously (55). Cells (106) were resuspended in 75 P.1 HBSS, 1%
FCS, 0.1% NaN3 . 1 Ftgof either 11,2-lys-biotin or unbiotinylated
control II,2 was added and the cells were incubated at 37°C for
10 min, followed by incubation on iceforan additional 60-90min.
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After washing, cells were stained with PE-conjugatedStreptavidin
(Becton DickinsonMonoclonal Center) and either IgGl-FITC or
anti-CD3-FITC to allow gating on the CD3-CD56* NK cell
subpopulation. FACS analysis was performed as described above.
'1s1IL2 Binding Assay.
￿
IL2 binding assays were performed as
described previously (6). 1211-IL2 was obtained from New England
Nuclear (Boston, MA) and had a specific activity of 0.94-3.6 x
106 cpm/pmol. 50 P1 of cells were combined with 50,ul of respec-
tive serial dilutions of
1211-11,2 in binding buffer (RPMI 1640, 10
mM Hepes, pH 7.2, 5 mg/mlBSA). Patients' cells were at concen-
trations ranging from 2.5 to 8.8 x 10'/ml, such that final con-
centrations in the assay ranged from 1.25 to 4.4 x 106/data point.
YT cells were at 8 x 106/ml. For experiments in which mAb
GL439was present, patient cells andYT cells were pretreated for
20 min on ice with GL439 at a final concentration of 50 lAg/ml.
For experiments in whichthe mAbTU27 was also present, a1:100
dilution of ascites fluid containing the antibody was included in
the pretreatment of the cells. Thecells and 1181-IIr2 were combined
for 12 min at 37°C and then spun through a 200-iAl layer of sili-
cone/paraffinoil (81:19).Cold competition values were determined
by including 2 Wg of unlabeled IL-2 (1.3 1AM final concentration)
in one assay tube with each cell sample and ranged from 0.2 to
0.4% of free counts. Thesebinding assayconditions are sufficient
to allow ->80% of themaximalbindingobserved afterincubation
for40 min to occur (unpublished observations), andareconsistent
with published data demonstrating a t~h of association to inter-
mediate affinity IIr2Rs of -4.5 min (16) . Binding data were ana-
lyzed according to the method of Scatchard (56).
Cell Surface Radioiodination andImmunoprecipitation.
￿
Before io-
dination cells were passed over Ficoll/Hypaque to insure good cell
viability, 10' cells were labeled with 1.0 mCi
'III (New England
Nuclear) using the glucose oxidase/lactoperoxidase method (En-
zymobeadsR), essentially according to manufacturer's (Bio-Rad
Laboratories, Richmond, CA) instructions. Briefly, cells were
resuspended in afinalvolume of 125 F,1 of PBS, followed by addi-
tion of 50 P.1 Enzymobeads, 25 ul 1% (3-D glucose, and 1.0 mCi
1151, After 20-25 min at room temperature, cells were pelleted,
washed four times with PBS, and solubilized in lysis buffer (20
mM Tris, pH 7.5, 140 mM NaCl, 0.1% deoxycholate, and 1%
NP-40) containing 1 mM PMSF and 2.5 Fcg/ml each aprotinin,
leupeptin, and antipain. Nuclei and debris were removed by cen-
trifugation for30 min at 100,000g. Lysates were precleared twice
by incubation with 25 14 (packed) mouse IgG agarose (Sigma Chem-
ical Co.), followed by two additional preclearings with 25 pl (packed)
Gammabind-protein G agarose (Genex, Gaithersburg, MD). Im-
munoprecipitations were performed by incubating aliquots of
precleared lysateswith 2-5 ul of ascites fluidcontaining either con-
trol IgG2a (UPC10) or anti-p70 (Mik /31) mAb. After 2-4 h on
ice, 501AIGammabindprotein Gagarose (1:1 in PBS, pH 7.4,0.05%
thimerosal) wasadded. After 1-2hat 4°C, precipitates were pelleted,
washed four times with lysis buffer, two times with 10 mM Tris,
pH 7.5, andresuspended in SDS-PAGE sample buffer. Afterboiling
for10 min, sampleswere analyzed on 9% SDS polyacrylamide gels
under reducing conditions, as described (57) .
Results
Flow Cytometric Analysis ofIL2R p55 andp70 Expression.
Pre- and post-IL-2 therapy PBL were examined for expres-
sion of both the a (Tac) anda (p70) subunits of the IL2R.
Consistent with our previous observations (44), circulating
PBL show a slight increase in Tac expression after in vivoA
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Figure 1 .
￿
Flow cytometric analysis of IL2R expression on pre- and post-11,2 therapy PBL . Cryopreserved PBL from patient 25 obtained before
(A) or 24 h after (B) 11,2 therapy andfrom patient 24 after IL2 therapy (C) were thawed and stained with the indicated antibodies: anti-CD25-FITC,
anti-CD3-PE, anti-CD56-PE, or the anti-p70 mAb TU27 . Staining with TU27 was followed by indirect fluorescent staining with GAM-FITC . Two-
color fluorescence was performed as described in Materials and Methods . Quadrant settings, distinguishing positive from background fluorescence,
were determined for each marker based on staining with isotype control antibodies (not shown) . The results shown for patients 24 (C) and 25 (A
and B) are representative of comparable data obtained from nine different patients (Table 1) .
Table 1.
￿
Summary of TU27 Fluorescence and '251-IL-2 Binding Results from Post-IL-2 Therapy PBL
TU27 MFI
For post-IL-2-therapy PBL, electronic gates were set on either the CD56+ or the CD3+ population . For YT cells, all viable cells were analyzed.
TU27 MFI was calculated by subtracting MFI of irrelevant control IgG1 from MFI of the TU27-stained cells . An MFI of 0 denotes that TU27
staining was not detectably different from background .
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,
Nay r
i
J
Patient
Percent
CD56+
CD3 +
subpopulation
CD56'
subpopulation Ka
PM
...I-IL-2 binding
Receptors/cell
14 81 0.6 41 510 800
15 42 0.9 39 ND ND
16 87 1.0 33 1,030 1,780
17 88 2.6 44 730 1,290
19 74 0 45 ND ND
21 74 0.4 45 ND ND
22 83 1.5 35 570 690
24 82 0 37 1,820 1,060
25 86 5.5 47 1,330 790
YT ND 13 1,410 12,800PATIENT 24
PATIENT 25
1172 therapy; all Tac+ cells were CD3+CD56- T cells (Fig. 1,
A and B) . No Tac expression was detected on the CD56'
CD3- NK cell population .
Using TU27, a mAb directed against the p70 /3 chain of
the IL2R, we and others have observed low but detectable
levels ofp70 on fresh NK cells obtained from healthy control
donors (33-35, 58, and S. Voss, unpublished observations) .
Similar results were obtained when PBL from cancer patients
were analyzed before in vivo IL2 therapy (Fig . 1 A) . These
data indicate that the pattern ofTU27 staining observed on
PBL obtained from patients before initiating IL-2 therapy is
similar to that observed withPBL from normal healthy donors.
In contrast, when post-therapy PBL were examined, a dra-
matic increase in p70 expression was observed (Fig. 1 B and
C) . This increase was limited to the CD56+ NK cell subset .
Similar results were obtained withPBL from seven other pa-
tients receiving continuous infusions of IL2 (Table 1) . In all
ofthe post-therapyPBL samples studied, brightTU27 staining
of the CD56+ population was observed (Table 1) . Identical
results were obtained using indirect fluorescent staining with
the TU27 mAb (Fig. 1) or with TU27 directly conjugated
to FITC (not shown) . Although some weak staining of
CD3+ T cells with TU27 was occasionally observed (Fig.
1 B), this observation has not been seen reproducibly with
PBL from other patients (Fig. 1 C, Table I) .
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Figure 2.
￿
Comparison of TU27 fluorescent staining on pre- and post-therapy PBL and YT cells . The relative levels of TU27 staining of pre- and
post-therapy PBLwere determined by indirect immunofluorescence . (A) Comparison ofpre- and post-therapy PBL stained withTU27 and gated only
on forward and side scatter to allow evaluation ofthe total lymphocyte population . (B) Comparison of the level ofTU27 staining ofpre- and post-therapy
CD56+ NK cells, performed by staining cells with anti-CD56-PE and TU27/GAM-FITC. Lymphocyte gates were set based on characteristic forward
and side light scatter properties, followed by gating on CD56' cells . TU27 MFI (calculated by subtracting background fluorescence of control IgGl)
on the pre-therapy CD56' populations were 10 and 14, as compared with post-therapy TU27 MFIs of 37 and 47 for patients 24 and 25, respectively.
(C) Comparison of the level of TU27 staining on post-therapy CD56' NK cells and YT cells. Forward and side scatter gates were set for YT cells ;
patient cells were gated as described above in B. In Band C, the histogram closest to the ordinate (IgGI) represents negative control staining ofpost-
therapy CD56 " PBL (B) and YT cells (C) . For clarity, only one control histogram is shown since controls forindividual samples were superimposable
(not shown) . For each sample, the number of events analyzed was similar (7,000-9,000), with the exception ofpre-therapy cells gated on the CD56`
population (1,500-1,700 events) . This difference is reflected in the difference in vertical scale between the pre- and post-therapy samples (B) .
The percentage of CD56+ cells in the pre-therapy PBL
was usually<20% (not shown), while 42-88% of the post-
therapy PBL from these patients were CD56+ (Table 1) . To
compare the level of TU27 staining of the CD56+ :ells
from pre- and post-therapy samples, we double stained cells
with anti-CD56 and TU27 and directly compared TU27
fluorescence intensity on the CD56+-gated populations. Fig.
2 shows data for TU27 staining of the ungated (A) and
CD56+-gated (B) PBL from two representative patients.
From Fig. 2 B, it is apparent that there is a dramatic increase
in p70 expression on the post-therapy CD56+ PBL relative
to pre-therapy CD56+ PBL . Comparison of the TU27 MFI
of pre- and post-therapy CD56+ cells revealed post-therapy
values that were 3.6-fold (Pt.24) and 3 .25-fold (Pt.25) greater
than the corresponding pre-therapy values. Fig. 2 C shows,
as a control population, YT cells : a well-characterized NK-like
cell line expressing a relatively high number (-12,000/cell)
of intermediate affinity IL2Rs (12, 13, 16, 17) . TheMFI for
TU27 staining of YT cells (MFI = 13) was less than that
for post-therapy cells (average MFI = 41 ± 6 ; Table 1), sug-
gesting that continuous administration of IL-2 in vivo might
result in a high level of expression on post-therapy PBL of
intermediate affinity IL2Rs (>12,000%ell, based on compar-
ison with YT cells) .
Because the level of p70 expression detected by FACS onthe post-therapy PBL samples is considerably higher than the
levels reported by others on various cell populations (33-35,
49, 52, 58), it was important to confirm our observations
with TU27 using another anti-p70 mAb. We therefore
repeated our flow cytometric analyses usingMik 01, an anti-
p70 mAb that was derived independently fromTU27 using
a different cell line (YT rather than TIrMor) as animmunogen
(52) . As presented in Fig . 3, staining with Mik (31 resulted
in the same increase in fluorescence intensity on the post-
therapy PBL as that previously observed with TU27 . This
increase was again restricted to the CD56+ NK cell sub-
population . Furthermore, the level of expression of p70 on
the patient's cells was again higher than that observed on
YT. These experiments have been repeated with PBL from
three patients with identical results and confirm our obser-
vations with TU27 . Further confirmation was also obtained
withMik (33, another anti-p70mAb that, in contrast to TU27
andMik (31, does not compete with IL-2 for binding to p70
(49, 52) . The results of staining with Mik (33 are presented
below as a component of the IL-2 binding analysis with bi-
otinylated IIr2 (shown in Fig. 9) .
Effect ofFc ReceptorBlocking on TU27 Staining ofPost-Therapy
PBL . We and others have reported increased numbers of
NK cells bearing Fcks ft-ykIIl, CD16) in post-IL2 therapy
PBL (47, 59) . Even though the FcyRIII expressed on NK
cells binds monomeric IgG poorly and monomeric murine
IgG at undetectably low levels (60, 61), it remained possible
that the apparent increase in p70 expression observed on the
post-therapy CD56+ NK cells was due to interaction of the
anti-p70 mAbs with the FcRs present on these cells .
To rule out this trivial explanation for the increase inTU27
staining observed, post-therapy PBL were pre-incubated with
heat-aggregated rabbit IgG to saturate all FcRs before staining
with TU27 . This FcR saturation treatment virtually elimi-
nated the ability of these cells to be recognized by the anti-
CD16 mAb, but had no effect on TU27 staining (Fig . 4) .
These results, together with the negligible staining observed
with appropriate isotype control mAbs, and the observation
that both CD16+ and CD16 - post-therapy CD56+ NK cell
subpopulations stain with TU27 with equal intensity (not
shown), argue that the increased staining with the anti-p70
mAbs reflects an increase in p70 (3 chain expression, and not
interaction of the anti-p70 mAbs with FeRs.
Proliferative Response ofPost-Therapy CD56+ PBL to Ifr2.
To evaluate the functional role of the p70 /3 chains expressed
on the CD56+ post-therapy PBL in the response of these
cells to 11,2, freshly obtained post-therapy PBL were sorted
to99% purity byFRCS using anti-CD56 and anti-CD5mAbs.
The CD56+CD5- cells were cultured for 48 h in increasing
concentrations of IL-2 in the presence of the anti-p70 mAb
TU27, the anti-p55 mAb GL439, or both . Representative
results from experiments performed on three separate occa-
sions are presented in Fig . 5 . TU27 completely inhibited the
proliferative response of the cells to 11,2, while GL439 had
no effect . In control experiments, GL439 produced a sub-
stantial inhibition of the proliferative response of fresh normal
PBL to IL-2 (40-75% inhibition at IL-2 concentrations <0.5
nM [not shown]) . CD5+CD56 - T cells sorted from the
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Figure 3 .
￿
Mik 01 staining ofpost-therapy PBL andYT cells. Post-therapy
PBL from patient 24 are shown stained with the anti-p70 mAb Mik (31
followed by GAM-FITC . Two-color fluorescence analysis was performed
as described in Materials and Methods with anti-CD3-PE (A) or anti-
CD56-PE (B) . Quadrant settingswere determined based on negative staining
of isotype control antibodies (not shown) . Comparison ofMik 01 staining
on YT cells and Pt . 24 post-therapy cells gated on the CD56+ popula-
tion is shown inC . The histogram closest to the ordinate (IgG2a) shows
isotype control staining on Pt. 24 PBL. Similar isotype control staining
for YT cells was observed (not shown) .
same post-1-2-therapy PBL in the same experiment and cultured
similarly showed no response to in vitro 11,2 (not shown),
consistent with previous results showing decreasedT cell re-
sponses by post-therapyPBL (44, 48) . These results confirm
our previous observations, performed with unseparated popu-
lations of cryopreserved post-therapy PBL (44, 47), and docu-
ment that the response of post-IL-2-therapy PBL to subse-
after In Vivo Interleukin 2- IgG
+ IgG
CD16
quent stimulation by IL-2 in vitro is mediated primarily by
the CD56+ NK cells and occurs predominantly through the
p70 IL-2R without involvement of the p55 Tic chain .
12s1IL2 Binding Studies.
￿
The observation that GL439 (a
mAb that inhibits IL-2 binding to the p55 Tic chain [51])
had no effect on the 11,2-induced proliferative response of
the post-therapy CD56+ NK cells (Fig . 5) suggested that
high affinity IL2Rs were not contributing functionally in
the proliferative response of the cells to IL2 . To determine
whether any high affinity binding sites, reflecting Tac involve-
ment, could be detected on post-therapy NK cells, 1251-IL2
binding assays were performed on post-therapy CD56+ NK
cells (purified byimmunomagnetic beads) in the presence and
absence of the anti-p55 mAb GL439 (Fig. 6) . GL439 inhibited
the high affinity component of the 1251-IL2 binding to YT
cells, a result consistent with previous studies demonstrating
low level expression of Tac on YT cells, predominantly in
the form of high affinity IL2R complexes (12, 13, 17) . In
contrast, GL439 had no effect on 1251-IL2 binding to the pa-
tient's cells . The absence of detectable high affinity binding
sites confirms that the post-therapy NK cells do not utilize
Tac/p70 high affinity receptor complexes for IL-2 binding.
Under these experimental conditions, the 1251-11,2 binding
to YT cells demonstrates that even a very low level of high
affinity binding on the patient's NK cells could have been
detected .
Further 1251-IL2 binding analyses were performed on
post-therapyPBL from six additional patients in order to de-
termine whether the increase in TU27 staining on the
CD56+ cells was accompanied by a corresponding increase
in IL2 binding sites . To reduce the contribution of the small
1107
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Figure 4.
￿
Effect ofFcR blocking on
TU27 fluorescence intensity. Post-
therapy PBL from patient 14 are shown
stained with either anti-CD16 (Leu-11a,
a mAb that recognizes the FcyRIII
found onNK cells [531) or TU27, after
preincubation with 10 mg/ml aggre-
gated rabbit Ig (+IgG) or control FACS
buffer (-IgG), as described in Materials
and Methods . The histogram outlined
by the dotted line represents isotype
control staining . The apparent dimly
positive stainingobserved with the anti-
CD16 mAb even in the presence of
saturating concentrations ofrabbit IgG
may be due to slight differences in the
fluorescein/protein (F/P) ratios of the
IgGl-FITC and anti-CD16-FITC an-
tibody/fluorochrome conjugates . For
analysis, electronic gates were set on the
CD3 - NK cell subpopulation, as de-
scribed in Fig. 2 .
proportion ofT cells (<20%) in these samples, the experi-
ments were performed in the presence ofGL439 . Since post-
therapy CD56+ cells express no detectable Tic (Fig. 1), their
proliferation in response to 1172 is negligibly affected by GL439
(Fig. 5), and no effect of GL439 on 1251-IL2 binding could
be demonstrated (Fig. 6), we reasoned that the antibody would
not alter the number or affinity of IL-2 binding sites on the
CD56+ subpopulation . In the samples on which subsequent
1251-IL2 binding assays were performed, CD56+ cells com-
prised an average of85% of the total cell population (Table
1) . Representative Scatchard plots of 1251-IL2 binding ob-
tained from two patient samples and from control YT cells
are shown in Fig . 7 . The patient sample curves were slightly
curvilinear, reflecting either minor heterogeneity in receptor
site affinities or experimental variability due to the very low
level ofbound radioisotope. Based on the results shown in
Figs . 5 and 6, analysis of these data and that ofthe four addi-
tional patients studied was limited to best fit lines representing
a single class of IL-2 binding sites (Table 1) .
Comparison of 1251-IL2 binding data for the patient sam-
ples and the control YT cells revealed that the patient cells
expressed intermediate affinity receptors with roughly the same
Kd as that of the receptors on the YT cells (Table 1) . De-
spite the high level of TU27 staining on the post-therapy
cells in reference to the control YT cells, suggesting more
p70 molecules on post-therapy PBL than on YT, only very
low numbers of intermediate affinity 11,2 binding sites were
detected on the post-therapyPBL (Table 1) . In fact, the number
ofbinding sites was in the range previously observed by others
for unstimulated NK cells (22, 58), although lower than that
determined by one group of investigators (34) . This 1251-IL250
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0
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Figure 5 .
￿
Effect of anti-p55 (GL439) and anti-p70 (TU27) mAbs on
proliferation of Pt.23 CD56+ post-therapy PBL . CD56+ post-therapy
cells, obtained after 2 wk of in vivo 11,2 therapy, were sorted by FACS.
TU27-FITC staining of the CD56+ cells revealed a TU27 MFI of 51
(compare with Table 1) . The sorted cells were incubated with increasing
concentrations of IL2 in the presence ofcontrol mAb (" ), GL439 (O),
TU27 (" ), or TU27+GL439 (0 ) . 10 5 cells/well were incubated with
mAbs for 60 min at 4°C before addition of IL2 . After culture for 42 h
at 37°C, cells were pulse labeled with 1 gCi of [313]thymidine for 18 h.
Error bars indicate SE of quadruplicate samples . GL439 was added at 50
Ntg/ml . Ascites fluid containing either TU27 or control IgG1 (MOPC
21; Sigma Chemical Co .) was used at a 1;640 dilution. In control experi-
ments, GL439 inhibited up to 75% ofthe proliferative response ofnormal
control PBL or anti-CD3-activated T cells to 11,2 (not shown) .
binding, like the intermediate affinity IL2 binding to the con-
trolYT cells, was blocked by preincubation of the cells with
the TU27 mAb (Fig . 7) .
These findings indicate a higher level of p70 expression
on the post-therapy NK cells than onYT cells, as determined
flow cytometrically using anti-p70mAbs . These results also
demonstrate that only a fraction of the p70 molecules ex-
pressed so abundantly on the surface of the post-therapy cells
could form functional intermediate affinity II,2Rs comparable
with those on YT cells . One explanation for this result, it
could be argued, is that under the experimental conditions
used in these studies (i.e., incubation for 12 min at 37°C),
equilibrium binding has not occurred, making estimates of
receptor number inaccurate . This is not likely to influence
our interpretation of the results presented in Table 1, how-
ever, which compare the level of IL-2 binding seen on pa-
tients' cells with that seen on YT cells handled in parallel
under identical conditions . Furthermore, in our experience,
>80-85% of the maximal binding (B..) observed after
longer incubation periods had occurred by 12 min, consis-
tent with a t~,, of association of -4.5 min to intermediate
affinity IL2Rs (16) . This slight difference in B.,. observed
after longer periods of incubation is unlikely to be the expla-
nation for the 10-15-fold differences in the level of intermediate
affinity IL2 binding seenwhen comparing the patients' NK
cells withYT cells. Furthermore, in one experiment in which
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Figure 6 .
￿
Scatchard analysis of high and intermediate affinity 1251-IL2
binding toYT and Pt . 25 PBL . Patient 25 PBL were depleted of T cells
by two rounds ofimmunomagneticbead depletion using anti-CD3 (OKT3)
and Dynalbeads coupled toGAM IgG, as described (44) . Upon reanalysis
after depletion, the Pt . 25 PBL were >95% pure for CD56+ NK cells .
Pt . 25 PBL and YT cells were incubated with increasing concentrations
of 1251-IL2 for 12 min at 37°C, followed by centrifugation through sili-
cone/paraffin oil . Before addition of 1251-IL2, cells were preincubated for
30 min on ice with 50 jug/ml GL439 (O) or no antibody (" ) .
incubations were carried out at 37°C for 25 min, a similar
low level of IL2 binding to the patient's NK cells relative
to YT was observed . It is thus apparent that the majority
of the molecules on the surface of the patients' NK cells rec-
ognized by the anti-p70 mAbs were incapable of the level
of intermediate affinity IL2 binding that would have been
expected under the experimental conditions used, based on
comparison with the level of anti-p70 mAb staining seen on
the YT cells.
Competitive Inhibition ofTU27mAbBinding by 11,2.
￿
Since
the flow cytometric data were collected on individual viable
cells and the 11,2 binding assays were performed with large
numbers of cells in bulk populations, it is difficult to make
direct quantitative comparisons between the apparently dis-
cordant results ofthese two assays. TU27 and Mik 01 binding
to post-therapy PBL was greater than that to YT cells by
FACS analysis, whereas the 1251-IL-2 binding to the patient
PBL was considerably less than the binding toYT cells. We
therefore felt it was important to evaluate IL2 binding on
the post-therapy PBL relative to YT cells using flow cytom-
etry. Since 11,2 and the TU27 mAb compete with one an-1109
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Figure 7.
￿
Scatchard analysis of representative
1 251-IL2 binding data . YT
cells (A) or freshly thawed cryopreserved patients' cells (B and C) were
incubated with increasing concentrations of 1251-IL2 for 12 min at 37°C,
followed by centrifugation through silicone/paraffin oil . Before addition
of 12SI-IL2, cells were preincubated for 20 min on ice with 50 pg/ml
GL439 (O) or 50 p,g/ml GL439 + 1:100 dilution of ascites fluid con-
taining TU27 (" ) . In control experiments, preincubation ofMT-1 cells,
a Tac+ p70- T cell line, with 50 ug/ml GL439 eliminated all specific 1251-
11,2 binding to thelow affinity Tac IIL2R subunit . Preincubation ofMT-1
cells with ascites fluid containing TU27 had no effect on the 1251-IL2
binding (not shown) .
other for binding to the p70 0 chain (49), preincubation of
cells with excess 11,2 should competitively inhibit TU27
binding to functional intermediate affinity IL2Rs. Indeed,
when YT cells were preincubated for 1-2 h at 4°C with
0.4-1.6 IAM IL2 and then stained with TU27, the MFI de-
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Figure 8 .
￿
Competition of TU27 staining by 11,2 . YT cells and Pt . 21
post-therapy PBL were incubated for 2 h at 4°C in the presence (+) or
absence (-) of 1 .6 I~g 11,2, before staining with TU27 and GAM-FITC.
Pt. 21 PBL were also stained with anti-CD56-PE. The effect of 11,2 on
TU27 fluorescence was evaluated on YT cells gated only on forward and
side scatter. Patient 21 PBL were additionally gated for expression ofCD56
after setting lymphocyte gates based on characteristic forward and side
scatter patterns. MFI values for the populations shown were calculated
as described in Materials and Methods : YT (-II,2)=10 .1 ; YT (+I1,2)=3.5;
Pt21 (-IL2)=34.9 ; Pt21 (+IL2)=29 .4 .
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Figure 9.
￿
FACS analysis ofIL2 binding using biotinylated IL2-lys. To
examine the distribution of IL-2 binding sites on the post-11,2 therapy
patient PBL, PBL from Pts . 5 and 25, as well asYT cells, were incubated
with 1 ug of either biotinylated 11,2-lys or control unbiotinylated IL2,
followed by staining with PE-conjugated Streptavidin . Pt . 5 and Pt . 25
PBL were also stained with anti-CD3-FITC to allow electronic gates to
be set on the CD3 - NK cell subpopulation . All cell populations were
gated on forward and side scatter before analysis. Indirect staining of the
same cell samples with Mik /33 and GAM-FITC is shown for comparison.
For Mik 03 staining, the patients' PBL were not gated on the CD56+
NK cell subpopulation . Control staining with either unbiotinylated I1r2
or IgG1 isotype control mAb is represented in the histograms shown by
dotted lines. Staining with either biotinylated IL2-lys or Mik 03 is repre-
sented by solid lines.creased by 65% (Fig. 8) . Alternatively, if the majority of the
p70 a chains recognized by TU27 on post-therapy PBL do
not have intermediate affinity IL2 binding properties, then
preincubation with excess 11,2 should minimally inhibitTU27
binding. In fact, when post-therapy cells were stained under
identical conditions as the controlYT cells, a decrease in MFI
of only 16% could be demonstrated (Fig. 8) . These experi-
ments were repeated with post-therapyPBL from four different
patients on three separate occasions with comparable results .
These data confirm the 1751-IL-2 binding data and indicate
that the majority of the molecules on the post-therapy
CD56' cells recognized by the anti-p70 mAb TU27 do not
bind IL2 with the intermediate affinity binding properties
of the majority of the p70 molecules present on control YT
cells.
FRCS Analysis ofCell Surface IL2 Binding with Biotinylated
IL2 . The 1251-IL2 binding data and the competitive inhi-
bition data presented thus far, while independently demon-
strating a low level of intermediate affinity IL-2 binding on
post-therapy NK cells, do not distinguish between uniform
distribution of a low number ofintermediate affinity binding
sites on all CD56 ` NK cells and a high number of inter-
mediate affinity binding sites expressed on only a few cells
in the CD56' population . To address this issue, experiments
were performed in which YT cells and post-therapy PBL were
incubated with IL2-lys-biotin (55), followed by fluorescent
staining with PE-conjugated streptavidin . Low level, homog-
enous IL2-lys-biotin staining of the patients' post-therapy
cells was observed when compared with the positive staining
of the controlYT cells (Fig . 9), indicating that the low level
of IL-2 binding detected in the bulk population in 1251-IL-2
binding assays is distributed uniformly throughout the CD56+
NK cell population . As a control, staining with the anti-p70
mAb Mik /33 was included (Fig. 9), confirming our earlier
observations with TU27 and Mik 01, and demonstrating that
despite low levels of IL2-lys-biotin binding relative to YT
cells, high levels of p70 (relative to YT) were expressed on
the patients' NK cells .
Immunoprecipitation ofp70 From Post-Therapy PBL and YT
The data presented thus far indicate a discrepancy between
the number ofintermediate affinity IL-2 binding sites present
on post-IL-2 therapy NK cells (measured by IL -2 binding)
and the level of the p70 IL2R6 expressed on the cell surface,
as detected by FACS analysis with anti-p70 mAbs. At least
one of the mAbs used in the FACS analyses (Mik (33) clearly
recognizes an epitope on p70 distinct from the epitope(s) rec-
ognized by Mik ail and TU27, since Mik /33, unlike Mik
01 and TU27, does not compete with IL2 for binding to
p70 . While it seems, therefore, unlikely that this panel of
anti-p70 mAbs is recognizing some molecule other than p70
on the post-therapy PBL, immunoprecipitation experiments
were undertaken to prove recognition of p70 . As shown in
Fig . 10, only the 70-75-kD IL2R a chain was specifically
precipitated by Mik (31 when tested with either YT cells or
post-therapy PBL from Pt.16 . Identical results have been ob-
tained with TU27 and Mik#3 (not shown) . The pattern of
migration of this 70-75-kD band, specifically precipitated by
the anti-p70 mAbs, is distinct from that described forCD16
Discussion
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(62), again making it unlikely that the increased p70 expres-
sion observed on the post-therapy patient PBL is due to FcR
interaction . Similar p70 immunoprecipitation results havenow
been obtained with PBL from six different patients (not
shown) .
These studies have evaluated the influence of in vivo IL2
administration on cell surface IL-2R expression . We and others
have previously documented an increase in both the absolute
number and the mean percentage of Tac+ PBL after IL2
therapy (28, 36, 45, 46) . Nevertheless, subsequent analyses
showed that the majority of the post-therapy CD56' NK
cells did not express detectable levels of Tac and maintained
this minimal Tac expression upon further in vitro culture with
IL-2 (44) . Furthermore, very low levels of soluble Tac were
released during in vitro stimulation, relative to pre-therapy
PBL, again suggesting a minimal role for Tac in the response
of in vivo activated NK cells to IL-2 (44) .
In the studies reported here, we have examined patients'
pre- and post-therapyPBL for the possibility ofincreased ex-
pression of the p70 /3 chain of the IL2R . When pre- and
post-therapy cells from the same patient were stained with
either anti Tac or the anti-p70 mAb TU27, we again observed
virtually no Tac+ CD56' cells ; the majority of the Tac ex-
pression was restricted to CD3+ T cells . In contrast, nearly
all of the CD56+ cells stained brightly with TU27, while
only dim staining ofCD3+ cells was seen. When electronic
gates were set on the CD56+CD3 - population, a compar-
ison of the TU27 staining on pre- vs . post-therapy cells re-
vealed an increase in TU27 fluorescence intensity on the post-
therapy population, suggesting increased expression of the
p70 0 chain on CD56+ NK cells induced by in vivo IL2 .
FcR blocking experiments, as well as immunoprecipitation
Figure 10.
￿
SDS-PAGE analysis of
radioiodinated cell surface proteins im-
munoprecipitated from YT and pa-
tient cell lysates. Pt 16 post-therapy
PBL and YT cells were cell surface
iodinated using the lactoperoxi-
dase/glucose oxidase method. After
pre-clearing with mouse IgG agarose
and Gammabind protein G agarose,
cell lysates were immunoprecipitated
with either control IgG2a mAb
(UPC10) or the anti-p70 mAb, Mik
,81 . Precipitates were washed exten-
sively, solubilized in SDS-PAGE
sample buffer containing O-ME, and
analyzed on a9% polyacrylamide gel .
After staining and fixing, the gelwas
dried and exposed to autoradiographic
film for 37 d. Standard molecular
weights (in kilodaltons) are indicated
at the left . A similar result was ob-
tained using TU27 as the immuno-
precipitating mAb (not shown) .data, demonstrated that this increased TU27 fluorescence
intensity was not due to interaction of the anti-p70 mAb
with FcRs.
A comparison of the TU27 staining of post-therapy cells
to YT cells revealed, to our surprise, that the post-therapy
cells were considerably brighter than YT cells when stained
withTU27 . When the flow cytometric analyses were repeated
withMik a1 and Mik /33, both independently derived anti-
p70 mAbs, identical results were obtained . Immunoprecipi-
tation experiments confirmed that the molecule recognized
by the anti-p70mAbs was the 70-75-kD IL2R,Q chain. How-
ever, onlylow levels of 11,2 binding to the post-therapy cells
could be demonstrated in 1251-IL2 binding assays, relative to
YT cells. Similar results have been obtained from six addi-
tional patients (not shown) . Scatchard analyses indicated an
average ofonly 790-1,290 intermediate affinity receptors/cell
in the post-therapy population, as compared with an average
of 12,000 receptors/YT cell . This unexpected result was
verified flow cytometrically when we observed that pre-
incubation of post-therapy cells with excess IL-2 had little
effect on TU27 staining, while similar treatment ofYT cells
resulted in a >60% decrease in TU27 staining. FRCS anal-
ysis of 11,2 binding to the post-therapy PBL using biotinylated
IL2 further demonstrated uniform distribution of the low
number of IL-2 binding sites detected in the 1251-IL-2 binding
assays.
In this report, we have also demonstrated the lack ofhigh
affinity IL2R expression on the post-therapy CD56+ NK
cells, confirming FACS data from our laboratory (44), and
from others (59), showing the lack of cell surface staining
by the anti Tac mAb. In addition, these cells appear to re-
spond to IL-2 exclusively through the p70 a chain and do
not appear to synthesize Tac and express high affinity IL-2R
after exposure to IL-2 in vitro, since proliferative responses
to 1172 were completely inhibited by the anti-p70 mAbTU27
and were unaffected by the antiTac mAb GL439 . Nagler et
al . (34) and Caligiuri et al . (35) have recently demonstrated
the presence of functional high affinity IL2Rs on a small subset
of resting NK cells that bear the CD56b°gh,CD16 - pheno-
type. These authors hypothesized that the high affinity
IL-2R-bearing CD56bright population of NK cells may rep-
resent a progenitor population capable of responding to low
doses of IL2 by expanding and maturing into FcR-bearing
NK cells . In most cases, the majority of the NK cells ex-
panded in vivo are CD56b°ght, 40-60% of which generally
coexpress FcR, as detected by the anti-CD16 mAb. Our in
vivo data are thus consistent with this hypothesis and sug-
gest that exposure to continuous infusions of IL-2 (during
which steady-state IL-2 levels of -30 U/ml are attained) may
lead to the expansion of CD56b°ght NK cells by virtue of the
circulating concentrations ofIL2 being sufficient to saturate
high affinity IL2R . If this is the case, our data would further
suggest that chronic exposure to 11,2 in vivo, while possibly
leading to the expansion ofan NK cell subset originally charac-
terized by the presence of high affinity IL2Rs, leads to the
loss of high affinity IL-2R expression on the NK cells that
return to the peripheral circulation from the lymphoid organs
after cessation of IL-2 therapy. This result is consistent with
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the observation that the CD56b°eht NK cells purified from
fresh peripheral blood that initially express high affinity I1T2Rs
rapidly downmodulate cell surface Tac expression upon in
vitro culture in IL-2 (J. Phillips and L . Lanier, personal com-
munication) . Another possibility, also consistent with these
data, would be the in vivo activation by IL-2 of a small NK
subpopulation that neither expresses nor utilizes the Tac mol-
ecule, with subsequent in vivo expansion enabling this ini-
tially small subset of NK cells to be the predominant NK
cell phenotype in the post-therapy PBL .
The molecular mechanisms regulating the level of p70 ex-
pression on the patients' post-therapy NK cells remain unclear.
Our data, demonstrating an elevation in p70 expression
without a corresponding elevation in the level ofintermediate
affinity 11,2 binding, suggest that the presence of the p70
# chain alone may not be the sole determinant ofintermediate
affinity IL2 binding. While both previous binding and cross-
linking studies indicated that p70 was the IL2 binding com-
ponent of the intermediate affinity IL2R, it appears from
our data that some other level of regulatory control may be
required to allow the p70 # chain to bind IL2 . One explana-
tion for the apparent discrepancy between the anti-p70 mAb
staining and 11,2 binding data might be expression of imma-
ture or structurally modified forms ofp70 that remain anti-
genically similar but lack IL-2 binding capabilities. This seems
less likely in view of the immunoprecipitation results showing
the 70-75-kD0 chain as the predominant species specifically
precipitated by Mik /31 (as well as Mik03 and TU27) from
whole cell lysates prepared from cell surface-iodinated post-
therapy patient PBL . Alternatively, it is conceivable that a
conformational change in the 0 chain could be introduced
by association with a putative y subunit or that a putative
y subunit might itself bind IL2 . Crosslinking studies with
'III-IL-2 have revealed numerous other bands in addition to
the 55-kD a and 70-kD a chains (1, 63, 64), any one ofwhich
could function to regulate the binding of IL-2 to the p70 0
chain . In immunoprecipitation experiments using the anti-
p70 mAb TU11, Sugamura and coworkers (65) have demon-
strated the association of a 64-kD molecule, p64 (which they
have termedMR y), with the p70 (3 chain of high affinity
IL-2R. Whether p64 is also a component of intermediate
affinity IIr2Rs remains to be determined . It is tempting to
speculate that p64, which could only be detected when IL-2
was bound to its receptor during the immunoprecipitation,
plays a role in regulating the binding of IL-2 to the p70a chain .
A number of other recent reports have also addressed the
possible involvement of additional IL-2R subunits in the for-
mation of functional IL2Rs (1, 52, 63, 64, 66-69) . Transfec-
tion experiments in which the cDNA encoding the p70 ,Q
chain was introduced into nonlymphoid cells failed to dem-
onstrate intermediate affinity IL-2 binding despite good cell
surface expression ofp70, while transfection of the p70 cDNA
into Jurkat cells, which express neither p55 nor p70, or into
MT-1 cells, which express the p55 a chain but little to no
p700 chain, produced functional intermediate and high affinity
receptors, respectively (67, 68, andB. Freimark andR. Robb,
unpublished observations) . Robb and coworkers (69) have
also recently characterized the kinetic binding properties ofp55/p70 IIr2R complexes expressed on cDNA-transfected
CHO cells . These receptors, while displaying equilibrium
bindingproperties characteristic oftrue high affinity I1r2Rs,
appear to be pseudo high affinity, in that bound ID2 has a
very rapid rate of dissociation from these receptors (at least
10-fold greater than the rate of dissociation seen withHUT
102 cells) (69) . Based on these data, one can speculate that
at least one function of additional Ilr2R subunits might be
to stabilize the IIr2/0 chain complex and slow the rate of
dissociation of IIr2 from p70. Whether this is the explana-
tion for the discrepant lowlevel of IL2 binding, despite the
high level ofp70 expression, observed on the post-II,2 therapy
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